Alan Meeker

Title: Alan Meeker: Innovator in Cancer Research

Introduction

Alan Meeker is a prominent inventor based in Pikesville, MD (US), known for his significant contributions to cancer research. He holds 2 patents that focus on the genetic underpinnings of brain cancer. His work has advanced the understanding of somatic mutations and their implications in various types of cancers.

Latest Patents

Meeker's latest patents delve into the somatic mutations in ATRX in brain cancer. He and his team determined the sequence of ATRX and DAXX in 447 cancers from various sites. They found mutations most commonly in pediatric glioblastoma multiformae (GBM) at a rate of 11.1%, adult GBM at 6.5%, oligodendrogliomas at 7.7%, and medulloblastomas at 1.5%. Their research showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. The alterations in ATRX or DAXX define a specific molecular pathway closely associated with an alternative telomere maintenance function in human cancers.

Career Highlights

Throughout his career, Alan Meeker has worked with prestigious institutions such as Johns Hopkins University and Duke University. His research has been pivotal in understanding the genetic factors that contribute to cancer progression and treatment.

Collaborations

Some of his notable coworkers include Hai Yan and Darell D Bigner, who have collaborated with him on various research projects.

Conclusion

Alan Meeker's innovative work in cancer research has made a significant impact on the field, particularly in understanding the genetic mutations associated with brain cancer. His contributions continue to influence ongoing research and potential therapeutic approaches.